CD19 and B-cell chronic lymphocytic leukemia: Even though B-cell tumorigenesis rarely leads to complete CD19 elimination [79, 80], it remains the primary antigen for CAR-T cell therapy in clinical studies targeting chronic lymphocytic leukemia (CLL).